+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Technetium-99m-sestamibi single agent localization versus high resolution ultrasonography for the preoperative localization of parathyroid glands in patients with primary hyperparathyroidism



Technetium-99m-sestamibi single agent localization versus high resolution ultrasonography for the preoperative localization of parathyroid glands in patients with primary hyperparathyroidism



American Surgeon 61(10): 882-888



Technetium 99m sestamibi, a newer radionuclide agent, has shown promise in parathyroid scintigraphy. Recent studies using technetium 99m sestamibi in conjunction with subtraction iodine I123 imaging have demonstrated accuracy for localizing parathyroid glands in patients with hyperparathyroidism. The effectiveness of technetium 99m sestamibi scanning as a single agent was compared prospectively with conventional high resolution ultrasonography for the preoperative localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Seventeen patients with primary hyperparathyroidism had preoperative evaluation with high resolution ultrasonography and technetium 99m sestamibi radionuclide scanning. All patients underwent bilateral neck exploration. Ultrasound results were made available to the surgeon preoperatively; however, technetium 99m sestamibi results were withheld unless specifically asked for by the surgeon intraoperatively. Comparison of the imaging studies were correlated with the operative and histological findings. Of 17 patients, 12 had solitary adenomas and four had diffuse hyperplasia. In one patient no abnormal glands were discovered. In patients with technetium 99m sestamibi localization, a solitary adenoma was identified correctly in 10 of 12 patients (83%). Three of four patients with diffuse hyperplasia had parathyroid sestamibi scans showing nonfocal or diffuse uptake in multiple glands. High resolution ultrasonography correctly identified only six of 12 patients with solitary parathyroid adenomas (50%). Of the patients with diffuse hyperplasia, two ultrasound studies showed a single enlarged gland, one study was negative, and one localized two questionable, enlarged glands. Technetium 99m sestamibi is effective as a single agent for preoperative parathyroid scintigraphy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 044520801

Download citation: RISBibTeXText

PMID: 7668462


Related references

Prospective comparison of technetium-99m-sestamibi/iodine-123 radionuclide scan versus high-resolution ultrasonography for the preoperative localization of abnormal parathyroid glands in patients with previously unoperated primary hyperparathyroidism. American Journal of Surgery 166(4): 369-373, 1993

Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clinical Endocrinology 57(2): 241-249, 2002

Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism. American Journal of Kidney Diseases 45(2): 344-352, 2005

Advantages of combined technetium-99m-sestamibi scintigraphy and high-resolution ultrasonography in parathyroid localization: Comparative study in 91 patients with primary hyperparathyroidism. European Journal of Endocrinology 143(6): 755-760, 2000

Subtraction scintigraphy with thallium-201 chloride and technetium-99m pertechnetate versus high resolution ultrasonography in the localization of the parathyroid glands in primary hyperparathyroidism. Medicina Clinica 99(20): 774-777, 1992

Use of technetium Tc 99m sestamibi and iodine 123 radionuclide scan for preoperative localization of abnormal parathyroid glands in primary hyperparathyroidism. Southern Medical Journal 87(3): 336-339, 1994

Localization of ectopic and supernumerary parathyroid glands in patients with secondary and tertiary hyperparathyroidism: surgical description and correlation with preoperative ultrasonography and Tc99m-Sestamibi scintigraphy. Brazilian Journal of Otorhinolaryngology 80(1): 29-34, 2014

A prospective evaluation of preoperative localization by technetium-99m sestamibi scintigraphy and ultrasonography in primary hyperparathyroidism. American Journal of Surgery 193(2): 155-159, 2007

Technetium-99m-sestamibi/pertechnetate subtraction scintigraphy vs ultrasonography for preoperative localization in primary hyperparathyroidism. European Radiology 12(3): 605-609, 2002

The use of preoperative localization of adenomas of the parathyroid glands by thallium-technetium subtraction scintigraphy, high-resolution ultrasonography and computed tomography. Surgery Gynecology and Obstetrics 168(2): 99, 1989

The value of scintigraphy and ultrasonography in the preoperative localization of parathyroid glands in patients with primary hyperparathyroidism and concomitant thyroid disease. Hormones 5(1): 42-51, 2006

The ineffectiveness of Technetium-99m-sestamibi for the pre-operative localization of parathyroid glands in neonatal primary hyperparathyroidism: case report. Jornal de Pediatria 75(4): 271-276, 2003

Single radionuclide imaging procedure with technetium 99m sestamibi double phase study for detection and localization of parathyroid adenomas in patients with primary hyperparathyroidism ph. Clinical & Investigative Medicine 15(4 Suppl.): A104, 1992

A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. Medicine 94(41): E1701, 2015

Preoperative parathyroid gland localization with technetium-99m sestamibi in secondary hyperparathyroidism. European Journal of Nuclear Medicine 24(12): 1494-1498, 1997